Lymphoma hub
@lymphomahub.bsky.social
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia.
New publication 📝 BRUIN CLL-314 phase III results, published in the Journal of Clinical Oncology, show that pirtobrutinib demonstrated noninferior ORR to ibrutinib (87.0% vs 78.5%; p < 0.0035) in TN or R/R BTKi-naïve CLL/SLL.
Learn more: https://loom.ly/jLklx8s
#leusm #lymsm #MedNews #MedEd
Learn more: https://loom.ly/jLklx8s
#leusm #lymsm #MedNews #MedEd
February 6, 2026 at 10:30 AM
New publication 📝 BRUIN CLL-314 phase III results, published in the Journal of Clinical Oncology, show that pirtobrutinib demonstrated noninferior ORR to ibrutinib (87.0% vs 78.5%; p < 0.0035) in TN or R/R BTKi-naïve CLL/SLL.
Learn more: https://loom.ly/jLklx8s
#leusm #lymsm #MedNews #MedEd
Learn more: https://loom.ly/jLklx8s
#leusm #lymsm #MedNews #MedEd
New publication📝 5-year follow-up results from the phase II JULIET trial, published in the Journal of Clinical Oncology, show tisagenlecleucel had an ORR of 53.0% in patients with R/R LBCL, with the median DoR not reached.
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
February 3, 2026 at 9:30 AM
New publication📝 5-year follow-up results from the phase II JULIET trial, published in the Journal of Clinical Oncology, show tisagenlecleucel had an ORR of 53.0% in patients with R/R LBCL, with the median DoR not reached.
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
New publication📝HOVON 158/NEXT STEP results, published in The Lancet Haematology, show MRD-guided ibrutinib + obinutuzumab intensification after ibrutinib + venetoclax achieved 60% CR/CRi with BM uMRD4 at 3 months in TN CLL.
Learn more: https://loom.ly/iVvKXk4
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/iVvKXk4
#lymphoma #lymsm #MedNews #MedEd
January 30, 2026 at 9:30 AM
New publication📝HOVON 158/NEXT STEP results, published in The Lancet Haematology, show MRD-guided ibrutinib + obinutuzumab intensification after ibrutinib + venetoclax achieved 60% CR/CRi with BM uMRD4 at 3 months in TN CLL.
Learn more: https://loom.ly/iVvKXk4
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/iVvKXk4
#lymphoma #lymsm #MedNews #MedEd
🚨News 🚨
Health Canada approves pirtobrutinib, a non-covalent BTKi, for the treatment of patients with R/R MCL and CLL/SLL who have received ≥2 prior lines of therapy.
Read more: https://loom.ly/jvX61wU
#lymsm #leusm #MedEd #MedNews
Health Canada approves pirtobrutinib, a non-covalent BTKi, for the treatment of patients with R/R MCL and CLL/SLL who have received ≥2 prior lines of therapy.
Read more: https://loom.ly/jvX61wU
#lymsm #leusm #MedEd #MedNews
January 28, 2026 at 5:30 PM
🚨News 🚨
Health Canada approves pirtobrutinib, a non-covalent BTKi, for the treatment of patients with R/R MCL and CLL/SLL who have received ≥2 prior lines of therapy.
Read more: https://loom.ly/jvX61wU
#lymsm #leusm #MedEd #MedNews
Health Canada approves pirtobrutinib, a non-covalent BTKi, for the treatment of patients with R/R MCL and CLL/SLL who have received ≥2 prior lines of therapy.
Read more: https://loom.ly/jvX61wU
#lymsm #leusm #MedEd #MedNews
New publication📝Phase III inMIND data, published in Lancet, show tafasitamab + lenalidomide + rituximab significantly improved median PFS vs placebo (22.4 vs 13.9 months; p < 0.0001) in R/R FL.
Learn more: https://loom.ly/uiZeapw
#lymsm #lymphoma #MedNews #MedEd
Learn more: https://loom.ly/uiZeapw
#lymsm #lymphoma #MedNews #MedEd
January 27, 2026 at 9:01 AM
New publication📝Phase III inMIND data, published in Lancet, show tafasitamab + lenalidomide + rituximab significantly improved median PFS vs placebo (22.4 vs 13.9 months; p < 0.0001) in R/R FL.
Learn more: https://loom.ly/uiZeapw
#lymsm #lymphoma #MedNews #MedEd
Learn more: https://loom.ly/uiZeapw
#lymsm #lymphoma #MedNews #MedEd
New publication📝Results from the CLL17 trial, published in @NEJM, show noninferior 3-year PFS with fixed-duration venetoclax + obinutuzumab or venetoclax + ibrutinib vs continuous ibrutinib in previously untreated CLL.
Learn more: https://loom.ly/iVvKXk4
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/iVvKXk4
#lymphoma #lymsm #MedNews #MedEd
January 20, 2026 at 5:30 PM
New publication📝Results from the CLL17 trial, published in @NEJM, show noninferior 3-year PFS with fixed-duration venetoclax + obinutuzumab or venetoclax + ibrutinib vs continuous ibrutinib in previously untreated CLL.
Learn more: https://loom.ly/iVvKXk4
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/iVvKXk4
#lymphoma #lymsm #MedNews #MedEd
New publication📝 Phase II MITHIC-FL2 first results, presented at #ASH2025, show ORR and CR rates were 92% and 82%, respectively, in patients with ND, high-burden FL treated with mosunetuzumab + zanubrutinib.
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
January 15, 2026 at 9:01 AM
New data📝Phase II preliminary results, presented by Anita Kumar at #ASH25, show the BOVen triplet combination achieved a 98% metabolic response rate in older patients with MCL, with a 2-year PFS of 86% and OS of 92%.
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
January 12, 2026 at 10:30 AM
The FDA has removed the REMS requirements for approved CAR T-cell therapies. Check out our visual abstract summarizing these changes: https://loom.ly/DAbLNQs
#lymsm #Lymphoma #MedNews #MedEd
#lymsm #Lymphoma #MedNews #MedEd
January 8, 2026 at 12:30 PM
The FDA has removed the REMS requirements for approved CAR T-cell therapies. Check out our visual abstract summarizing these changes: https://loom.ly/DAbLNQs
#lymsm #Lymphoma #MedNews #MedEd
#lymsm #Lymphoma #MedNews #MedEd
🚨 News 🚨
The FDA clears an IND application for APG-3288, a novel BTK-targeted protein degrader, for the treatment of relapsed/refractory B-cell malignancies.
Read more: https://loom.ly/_qG9hog
#Lymphoma #Lymsm #MedNews
The FDA clears an IND application for APG-3288, a novel BTK-targeted protein degrader, for the treatment of relapsed/refractory B-cell malignancies.
Read more: https://loom.ly/_qG9hog
#Lymphoma #Lymsm #MedNews
January 7, 2026 at 5:04 PM
🚨 News 🚨
The FDA clears an IND application for APG-3288, a novel BTK-targeted protein degrader, for the treatment of relapsed/refractory B-cell malignancies.
Read more: https://loom.ly/_qG9hog
#Lymphoma #Lymsm #MedNews
The FDA clears an IND application for APG-3288, a novel BTK-targeted protein degrader, for the treatment of relapsed/refractory B-cell malignancies.
Read more: https://loom.ly/_qG9hog
#Lymphoma #Lymsm #MedNews
Read our latest overview of class effects, treatment guidelines, and real-world evidence for BTKi in patients with CLL: https://loom.ly/Zlwwbfs
#leusm #lymsm #MedEd #MedNews
#leusm #lymsm #MedEd #MedNews
January 2, 2026 at 9:00 AM
Read our latest overview of class effects, treatment guidelines, and real-world evidence for BTKi in patients with CLL: https://loom.ly/Zlwwbfs
#leusm #lymsm #MedEd #MedNews
#leusm #lymsm #MedEd #MedNews
In our latest podcast, Joshua Brody shared his key highlights in lymphoma and CLL from #ASH25.
Listen here: https://loom.ly/a0CqZnU
#lymsm #lymphoma #MedEd
Listen here: https://loom.ly/a0CqZnU
#lymsm #lymphoma #MedEd
December 31, 2025 at 4:30 PM
In our latest podcast, Joshua Brody shared his key highlights in lymphoma and CLL from #ASH25.
Listen here: https://loom.ly/a0CqZnU
#lymsm #lymphoma #MedEd
Listen here: https://loom.ly/a0CqZnU
#lymsm #lymphoma #MedEd
New data📝Phase III BRUIN CLL-313 findings, presented by Wojciech Jurczak at #ASH25, show pirtobrutinib significantly improved PFS vs BR in patients with treatment-naïve CLL/SLL (HR, 0.20; 95% CI, 0.11–0.37; p < 0.0001).
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
December 29, 2025 at 12:30 PM
Joshua Brody shared his key highlights in lymphoma and CLL from #ASH25.
Watch here: https://loom.ly/OSJsgR8
#lymsm #lymphoma #MedEd
Watch here: https://loom.ly/OSJsgR8
#lymsm #lymphoma #MedEd
December 29, 2025 at 9:01 AM
Joshua Brody shared his key highlights in lymphoma and CLL from #ASH25.
Watch here: https://loom.ly/OSJsgR8
#lymsm #lymphoma #MedEd
Watch here: https://loom.ly/OSJsgR8
#lymsm #lymphoma #MedEd
Alexey Danilov discussed results from the phase I study of bexobrutideg, a novel BTK degrader, in patients with R/R CLL, which were presented at #ASH25.
Watch here: https://loom.ly/M45g2y4
#lymsm #leusm #MedEd
Watch here: https://loom.ly/M45g2y4
#lymsm #leusm #MedEd
December 27, 2025 at 12:00 PM
Alexey Danilov discussed results from the phase I study of bexobrutideg, a novel BTK degrader, in patients with R/R CLL, which were presented at #ASH25.
Watch here: https://loom.ly/M45g2y4
#lymsm #leusm #MedEd
Watch here: https://loom.ly/M45g2y4
#lymsm #leusm #MedEd
Susan O’Brien, @ChaoCompCancer @UCIrvineHealth, discussed results from the CAPTIVATE trial of ibrutinib + venetoclax in patients with CLL.
Watch the full video here: https://loom.ly/F7tWpYY
#leusm #lymsm #MedNews #MedEd
Watch the full video here: https://loom.ly/F7tWpYY
#leusm #lymsm #MedNews #MedEd
December 23, 2025 at 9:01 AM
Susan O’Brien, @ChaoCompCancer @UCIrvineHealth, discussed results from the CAPTIVATE trial of ibrutinib + venetoclax in patients with CLL.
Watch the full video here: https://loom.ly/F7tWpYY
#leusm #lymsm #MedNews #MedEd
Watch the full video here: https://loom.ly/F7tWpYY
#leusm #lymsm #MedNews #MedEd
🚨 NEWS 🚨
FDA approves a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial.
Read more: https://loom.ly/p7QgFmU
#lymphoma #lymsm #MedNews #MedEd
FDA approves a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial.
Read more: https://loom.ly/p7QgFmU
#lymphoma #lymsm #MedNews #MedEd
December 22, 2025 at 5:06 PM
🚨 NEWS 🚨
FDA approves a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial.
Read more: https://loom.ly/p7QgFmU
#lymphoma #lymsm #MedNews #MedEd
FDA approves a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial.
Read more: https://loom.ly/p7QgFmU
#lymphoma #lymsm #MedNews #MedEd
🚨 NEWS 🚨
Japan's Ministry of Health, Labour and Welfare approves tafasitamab in combination with rituximab + lenalidomide for adult patients with R/R FL, based on data from the phase III inMIND trial.
Read more: https://loom.ly/n4AYOKI
#lymphoma #lymsm #mednews
Japan's Ministry of Health, Labour and Welfare approves tafasitamab in combination with rituximab + lenalidomide for adult patients with R/R FL, based on data from the phase III inMIND trial.
Read more: https://loom.ly/n4AYOKI
#lymphoma #lymsm #mednews
December 22, 2025 at 4:48 PM
🚨 NEWS 🚨
Japan's Ministry of Health, Labour and Welfare approves tafasitamab in combination with rituximab + lenalidomide for adult patients with R/R FL, based on data from the phase III inMIND trial.
Read more: https://loom.ly/n4AYOKI
#lymphoma #lymsm #mednews
Japan's Ministry of Health, Labour and Welfare approves tafasitamab in combination with rituximab + lenalidomide for adult patients with R/R FL, based on data from the phase III inMIND trial.
Read more: https://loom.ly/n4AYOKI
#lymphoma #lymsm #mednews
The Lymphoma Hub was pleased to speak with Alexey Danilov at #ASH25. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL?
Watch the full video here: https://loom.ly/M45g2y4
#lymsm #leusm #MedEd
Watch the full video here: https://loom.ly/M45g2y4
#lymsm #leusm #MedEd
December 22, 2025 at 3:06 PM
The Lymphoma Hub was pleased to speak with Alexey Danilov at #ASH25. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL?
Watch the full video here: https://loom.ly/M45g2y4
#lymsm #leusm #MedEd
Watch the full video here: https://loom.ly/M45g2y4
#lymsm #leusm #MedEd
What are the class effects, treatment guidelines, and real-world evidence for BTKi in patients with CLL?
Read our latest article here: https://loom.ly/Zlwwbfs
#leusm #lymsm #MedEd #MedNews
Read our latest article here: https://loom.ly/Zlwwbfs
#leusm #lymsm #MedEd #MedNews
December 22, 2025 at 12:30 PM
What are the class effects, treatment guidelines, and real-world evidence for BTKi in patients with CLL?
Read our latest article here: https://loom.ly/Zlwwbfs
#leusm #lymsm #MedEd #MedNews
Read our latest article here: https://loom.ly/Zlwwbfs
#leusm #lymsm #MedEd #MedNews
In our latest podcast, Alexey Danilov discusses results from the ongoing phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL, presented at #ASH25
Listen here: https://loom.ly/BLdORcI
#lymsm #leusm #MedEd
Listen here: https://loom.ly/BLdORcI
#lymsm #leusm #MedEd
December 20, 2025 at 10:00 AM
In our latest podcast, Alexey Danilov discusses results from the ongoing phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL, presented at #ASH25
Listen here: https://loom.ly/BLdORcI
#lymsm #leusm #MedEd
Listen here: https://loom.ly/BLdORcI
#lymsm #leusm #MedEd
Catch up on the latest developments in aggressive B-cell NHL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/POS6cqk
#lymsm #leusm #MedicalCongress
#lymsm #leusm #MedicalCongress
December 19, 2025 at 5:15 PM
Catch up on the latest developments in aggressive B-cell NHL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/POS6cqk
#lymsm #leusm #MedicalCongress
#lymsm #leusm #MedicalCongress
Catch up on the latest developments in indolent and mantle cell NHL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/FTOLNe8
#lymsm #leusm #MedicalCongress
#lymsm #leusm #MedicalCongress
December 19, 2025 at 3:13 PM
Catch up on the latest developments in indolent and mantle cell NHL from #ASH25, with social media coverage from the Lymphoma Hub: https://loom.ly/FTOLNe8
#lymsm #leusm #MedicalCongress
#lymsm #leusm #MedicalCongress